Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin

Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, discusses the POLARIX trial (NCT03274492), which focuses on the efficacy of rituximab-cyclophosphamide, doxorubicin, and prednisone (R-CHP) amongst subgroups of patients with diffuse large B-cell lymphoma (DLBCL). The findings show higher responses in the subset of patients categorized as activated B-cell (ABC) according to gene expression profiling. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.